Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer-Reference-Cited by-同舟云学术

Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer

Published:2021-01-02 Issue:2 Volume:112 Page:847-858
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kobayashi Sohei¹²^ORCID,Hiwasa Takaki³,Ishige Takayuki¹,Kano Masayuki⁴,Hoshino Tyuji⁵,Rahmutulla Bahityar⁶^ORCID,Seimiya Masanori²,Shimada Hideaki⁷^ORCID,Nomura Fumio¹,Matsubara Hisahiro⁴,Matsushita Kazuyuki¹^ORCID

Affiliation:

1. Department of Laboratory Medicine & Division of Clinical Genetics Chiba University Hospital Chiba Japan

2. Department of Medical Technology & Sciences School of Health Sciences at Narita International University of Health and Welfare Chiba Japan

3. Department of Neurological Surgery Graduate School of Medicine Chiba University Chiba Japan

4. Department of Frontier Surgery Graduate School of Medicine Chiba University Chiba Japan

5. Department of Physical Chemistry Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan

6. Department of Molecular Oncology Graduate School of Medicine Chiba University Chiba Japan

7. Department of Gastroenterological Surgery Graduate School of Medicine Toho University Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14767

Reference54 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

3. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

4. Human neoplasms elicit multiple specific immune responses in the autologous host;Sahin U;Proc Natl Acad Sci USA,1995

5. Serum anti‐myomegalin antibodies in patients with esophageal squamous cell carcinoma;Shimada H;Int J Oncol,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combinational antibody detection approach increases the clinical validity of colorectal cancer screening;Journal of Clinical Laboratory Analysis;2023-11

2. A tumor-associated autoantibody panel for the detection of non-small cell lung cancer;Frontiers in Oncology;2022-12-02

3. Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis;Frontiers in Oncology;2022-05-17

4. Tumour- associated autoantibodies as prognostic cancer biomarkers- a review;Autoimmunity Reviews;2022-04